FDA label
What is Rezurock used for?
Rezurock contains belumosudil. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Rezurock?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Rezurock, tablet
Indications and Usage, quoted from the label by Kadmon Pharmaceuticals, LLC (NDA214783). Cross-references to other label sections are left out.
REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Source: DailyMed label, set id 102e4ef4-7f84-4e34-8df1-479c24d1575d, version 11, effective April 7, 2026. NDC 79802-200, one of 1 listing for this product.
Questions
What is Rezurock used for?
The FDA label says: “REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.”
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.